HRP20130917T1 - 5-(2-{[6-(2,2-difluoro-2-feniletoksi)heksil]amino}-1-hidroksietil)-8-hidroksikinolin-2-(1h)-on za lijeäśenje pluä†ne funkcije - Google Patents

5-(2-{[6-(2,2-difluoro-2-feniletoksi)heksil]amino}-1-hidroksietil)-8-hidroksikinolin-2-(1h)-on za lijeäśenje pluä†ne funkcije Download PDF

Info

Publication number
HRP20130917T1
HRP20130917T1 HRP20130917AT HRP20130917T HRP20130917T1 HR P20130917 T1 HRP20130917 T1 HR P20130917T1 HR P20130917A T HRP20130917A T HR P20130917AT HR P20130917 T HRP20130917 T HR P20130917T HR P20130917 T1 HRP20130917 T1 HR P20130917T1
Authority
HR
Croatia
Prior art keywords
fev1
stereoisomers
hydroxyquinolin
phenylethoxy
difluoro
Prior art date
Application number
HRP20130917AT
Other languages
English (en)
Croatian (hr)
Inventor
Thorsten Ruf
Eric Massana Montejo
Original Assignee
Almirall, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall, S.A. filed Critical Almirall, S.A.
Publication of HRP20130917T1 publication Critical patent/HRP20130917T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20130917AT 2009-02-18 2010-02-18 5-(2-{[6-(2,2-difluoro-2-feniletoksi)heksil]amino}-1-hidroksietil)-8-hidroksikinolin-2-(1h)-on za lijeäśenje pluä†ne funkcije HRP20130917T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
PCT/EP2010/001026 WO2010094483A1 (en) 2009-02-18 2010-02-18 5- (2-{ [6- (2, 2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl) -8-hydroxyquinolin-2 (ih)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
HRP20130917T1 true HRP20130917T1 (hr) 2013-11-08

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130917AT HRP20130917T1 (hr) 2009-02-18 2010-02-18 5-(2-{[6-(2,2-difluoro-2-feniletoksi)heksil]amino}-1-hidroksietil)-8-hidroksikinolin-2-(1h)-on za lijeäśenje pluä†ne funkcije

Country Status (32)

Country Link
US (2) US20120029014A1 (https=)
EP (2) EP2221055A1 (https=)
JP (1) JP2012518019A (https=)
KR (1) KR20110123742A (https=)
CN (2) CN105326838A (https=)
AR (1) AR075432A1 (https=)
AU (1) AU2010214854A1 (https=)
CA (1) CA2749059C (https=)
CL (1) CL2011002001A1 (https=)
CO (1) CO6361939A2 (https=)
CY (1) CY1114484T1 (https=)
DK (1) DK2398473T3 (https=)
EA (1) EA022442B1 (https=)
EC (1) ECSP11011336A (https=)
ES (1) ES2430596T3 (https=)
HR (1) HRP20130917T1 (https=)
IL (1) IL213979A0 (https=)
ME (1) ME01757B (https=)
MX (1) MX2011008577A (https=)
MY (1) MY155657A (https=)
NZ (1) NZ593727A (https=)
PE (1) PE20120419A1 (https=)
PL (1) PL2398473T3 (https=)
PT (1) PT2398473E (https=)
RS (1) RS52951B (https=)
SG (2) SG173091A1 (https=)
SI (1) SI2398473T1 (https=)
TW (2) TW201031408A (https=)
UA (1) UA103370C2 (https=)
UY (1) UY32414A (https=)
WO (1) WO2010094483A1 (https=)
ZA (1) ZA201104654B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
EP0640354B1 (en) 1990-09-26 2001-12-05 Pharmachemie B.V. Whirl chamber powder inhaler
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
WO1994014492A2 (en) 1992-12-18 1994-07-07 Schering Corporation Inhaler for powdered medications
MX9707864A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
PT837710E (pt) 1995-06-21 2002-05-31 Sofotec Gmbh & Co Kg Cartucho de po farmaceutico com dispositivo de doseamento integrado e inalador para medicamentos em po
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
JP2012518019A (ja) 2012-08-09
UY32414A (es) 2010-07-30
AU2010214854A1 (en) 2011-07-21
KR20110123742A (ko) 2011-11-15
CA2749059A1 (en) 2010-08-26
HK1159990A1 (en) 2012-08-10
EP2221055A1 (en) 2010-08-25
CA2749059C (en) 2017-08-01
CL2011002001A1 (es) 2011-11-11
PT2398473E (pt) 2013-09-30
TW201442711A (zh) 2014-11-16
UA103370C2 (uk) 2013-10-10
MY155657A (en) 2015-11-13
NZ593727A (en) 2013-07-26
PE20120419A1 (es) 2012-05-09
CN102325530A (zh) 2012-01-18
IL213979A0 (en) 2011-08-31
EP2398473B1 (en) 2013-07-24
ZA201104654B (en) 2012-02-29
CN105326838A (zh) 2016-02-17
CY1114484T1 (el) 2016-10-05
AR075432A1 (es) 2011-03-30
EA201101210A1 (ru) 2012-03-30
RS52951B (sr) 2014-02-28
TW201031408A (en) 2010-09-01
SI2398473T1 (sl) 2013-11-29
ECSP11011336A (es) 2011-10-31
US20120029014A1 (en) 2012-02-02
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
US20140343097A1 (en) 2014-11-20
WO2010094483A1 (en) 2010-08-26
ES2430596T3 (es) 2013-11-21
ME01757B (me) 2014-09-20
SG2014012827A (en) 2014-04-28
CO6361939A2 (es) 2012-01-20
PL2398473T3 (pl) 2013-12-31
DK2398473T3 (da) 2013-10-21
MX2011008577A (es) 2011-09-06
SG173091A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
HRP20130917T1 (hr) 5-(2-{[6-(2,2-difluoro-2-feniletoksi)heksil]amino}-1-hidroksietil)-8-hidroksikinolin-2-(1h)-on za lijeäśenje pluä†ne funkcije
CA2676456A1 (en) Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
HRP20120832T1 (hr) Antagonisti muskarinskih acetilkolinskih receptora
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
JP2014521658A5 (https=)
NZ606977A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
PH12014500417A1 (en) 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
CN100518775C (zh) 一种治疗咳喘的药物组合物及其制剂
CN102133319A (zh) 一种平喘止咳的药物及其制备方法
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
CA2708043A1 (en) Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
RU2009141168A (ru) Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна
JP2010523662A5 (https=)
CN103735884B (zh) 一种治疗咳嗽的药物及其制备
EA201070336A1 (ru) Ингаляционный азтреонам лизин для лечения нарушений, снижающих качество жизни, обусловленное состоянием здоровья при заболеваниях легких
CN103223058B (zh) 牡荆子总黄酮提取物及其制备方法和医药用途
WO2016197467A1 (zh) 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2016041439A1 (zh) 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂
CN103405633A (zh) 中药组合物及其应用
Vrijsen et al. NIV improves sleep fragmentation in patients with ALS